Comparative Pharmacology
Head-to-head clinical analysis: FLUCONAZOLE IN DEXTROSE 5 IN PLASTIC CONTAINER versus GYNE LOTRIMIN 3 COMBINATION PACK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUCONAZOLE IN DEXTROSE 5 IN PLASTIC CONTAINER versus GYNE LOTRIMIN 3 COMBINATION PACK.
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER vs GYNE-LOTRIMIN 3 COMBINATION PACK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluconazole selectively inhibits fungal cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This leads to increased membrane permeability and inhibition of fungal growth.
Clotrimazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and increasing membrane permeability. The combination pack includes an insert for vaginal use and a topical cream for external use.
200-400 mg IV once daily; for candidemia or invasive candidiasis, loading dose of 800 mg IV on day 1, then 400 mg IV once daily.
Vaginal suppository: 200 mg at bedtime for 3 nights; topical cream (2%): apply intravaginally once daily for 3 nights.
None Documented
None Documented
Terminal elimination half-life approximately 30 hours (range 20-50 hours). Prolonged in renal impairment (up to 98 hours in CrCl <20 mL/min).
Terminal half-life of absorbed clotrimazole is approximately 3.5-6 hours; clinically, topical application maintains local concentrations without reliance on systemic half-life.
Renal: 80% unchanged drug; feces: 11%; biliary: minor.
Clotrimazole: ~0.03% of topical dose excreted renally as metabolites; majority eliminated in feces via biliary excretion. Vaginal administration: minimal systemic absorption (<3%), with absorbed drug primarily metabolized hepatically and excreted in bile/feces.
Category A/B
Category C
Azole Antifungal
Azole Antifungal